Zenosense, Inc (fka ZENO) (ZENO)

[derkampfer]

McM. Interesting analysis. Not sure if profit of $1000 per test is at all realistic. Even if 1/10 then your target share price is $40, which from $.50 is still impressive.

Yes the team is impressive, and that’s CEO Tom Barr in the UK with Bio-AMD ($BIAD). They did all the lab work and the tech is their development. BIAD is 60% of the MML partnership and ZENO 40%.

Both stand to profit handsomely from this breakthrough technology. Which most importantly will serve as an immediate heart attack risk assessment device which the world currently doesn’t have. Countless lives may be saved if a heart attack can be detected early enough.

I’d image next step is placing the technology in a physical device and finding partners to manufacture it. BIAD already has US and Chinese Patents granted protecting the technology.

Well done team on a breakthrough tech.

Excellent results.